Valutazioni biologiche su pazienti con tumori rari candidati al trattamento con cellule dendritiche

Title

Code

IRSTB108 - BioRaV

Type

Sperimentale

Start Year

2020

Status

In Corso

Principal Investigator

Description

Studio promosso da Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori – Meldola (FC).

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. IRSTB108 - BioRaV

Monday 12 September 2022, 17:42

PG0015932_2020_IRSTB108.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Valutazioni biologiche su pazienti con tumori rari candidati al trattamento con cellule dendritiche

Principal Investigator

Description

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Valutazioni biologiche su pazienti con tumori rari candidati al trattamento con cellule dendritiche

Principal Investigator

Description

Documents and Videos attachament

You might also be interested in